Side-by-side · Research reference
BPC-157vsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed9/53 cited
BFDA-ApprovedVerified15/53 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
BPC-157
Semaglutide
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014Sikiric 2018
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
No known endogenous receptor; mechanism still under investigation
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
—
—
02Dosage Protocols
Parameter
BPC-157
Semaglutide
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
—
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
Once weekly, same day each week
Lower / starter dose
200 mcg / day
Conservative starter for new users.
—
Evidence basis
Animal-strong + Phase 2 clinicalSikiric 2018Hwang 2016
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
Indefinite for chronic indication
Discontinuation results in weight regain.
Reconstitution
Bacteriostatic water, 1–2 mL
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
Any time of day, with or without food
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
~7 days (168 h)WEGOVY (semaglutide) injection 2021
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
04Side Effects & Safety
Parameter
BPC-157
Semaglutide
Injection site reaction
Mild irritation (anecdotal)
Mild erythema, pruritus
GI symptoms
None reported in PL-14736 Phase 2
Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021
Cardiovascular
Not reported
—
Antibody formation
No data (no long-term human trials)
—
Long-term safety
Unknown beyond Phase 2 trial duration
—
Drug interactions
None established
—
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
BPC-157
Semaglutide
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)